Company Information

JAGSONPAL PHARMACEUTICALS LTD.

NSE : JAGSNPHARMBSE : 507789ISIN CODE : INE048B01027Industry : Pharmaceuticals & DrugsHouse : Jagsonpal
BSE326.20-4.75 (-1.44 %)
PREV CLOSE ( ) 330.95
OPEN PRICE ( ) 335.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1540
TODAY'S LOW / HIGH ( )324.30 337.90
52 WK LOW / HIGH ( )270.05 513.9
NSE325.60-8.1 (-2.43 %)
PREV CLOSE( ) 333.70
OPEN PRICE ( ) 336.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18009
TODAY'S LOW / HIGH( ) 324.25 336.55
52 WK LOW / HIGH ( )273.6 514.85
ChairmanHarsha Raghavan
Managing DirectorManish Gupta
Company SecretaryAbhishek Joshi
Chairman EmeritusRajpal Singh
Non Executive Independent DirectorDebasis Bikash Nandy
Pallavi Dinodia Gupta
Radhika Madhukar Dudhat
Non Independent & Non Executive DirectorPrithipal Singh Kochhar
Incorporation Year : 17-08 1978

Registered Office :

Address : T 210 J,Shabpur Jat, New Delhi,
Delhi-110049 .

Phone : 011-46181100 / 46109900

Email :  cs@jagsonpal.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.